Genetic predictors of response to therapy in childhood asthma

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Asthma is a common chronic condition in children, where the response to treatment can be heterogeneous within a population. Genetic variations may partly explain the inconsistent response to asthma treatment between individuals. There is a relatively small but consistent body of literature linking genetic variations to improved response to different classes of asthma treatment, including short- and long-acting ß-agonists, corticosteroids, and leukotriene modifiers. In most cases, the advantage conferred by a single genetic mutation for treatment response is relatively small; the Arg16Gly single nucleotide polymorphism of the ß2-adrenoceptor is the exception to this rule and is associated with a marked difference in response to short-acting ß-agonists. Pharmacogenetic studies have only recently been undertaken in asthmatic individuals, and much more work is required before clinical applications arise. Future genome-wide association (GWA) studies and randomized controlled trials in genetically susceptible populations will determine whether asthma treatment can be tailored to an individual based on their DNA. The aim of the present paper is to review pharmacogenetic studies concerning asthma medications, with a primary focus on studies involving children.
Original languageEnglish
Pages (from-to)127-135
Number of pages9
JournalMolecular Diagnosis & Therapy
Volume13
Issue number2
DOIs
Publication statusPublished - Apr 2009

Fingerprint

Asthma
Therapeutics
Leukotrienes
Genome-Wide Association Study
Adrenergic Receptors
Population
Single Nucleotide Polymorphism
Adrenal Cortex Hormones
Randomized Controlled Trials
Mutation
DNA
Pharmacogenomic Testing

Cite this

Genetic predictors of response to therapy in childhood asthma. / Turner, Stephen W.

In: Molecular Diagnosis & Therapy, Vol. 13, No. 2, 04.2009, p. 127-135.

Research output: Contribution to journalArticle

@article{ef81317564cb4afbbbdebd15d13395c6,
title = "Genetic predictors of response to therapy in childhood asthma",
abstract = "Asthma is a common chronic condition in children, where the response to treatment can be heterogeneous within a population. Genetic variations may partly explain the inconsistent response to asthma treatment between individuals. There is a relatively small but consistent body of literature linking genetic variations to improved response to different classes of asthma treatment, including short- and long-acting {\ss}-agonists, corticosteroids, and leukotriene modifiers. In most cases, the advantage conferred by a single genetic mutation for treatment response is relatively small; the Arg16Gly single nucleotide polymorphism of the {\ss}2-adrenoceptor is the exception to this rule and is associated with a marked difference in response to short-acting {\ss}-agonists. Pharmacogenetic studies have only recently been undertaken in asthmatic individuals, and much more work is required before clinical applications arise. Future genome-wide association (GWA) studies and randomized controlled trials in genetically susceptible populations will determine whether asthma treatment can be tailored to an individual based on their DNA. The aim of the present paper is to review pharmacogenetic studies concerning asthma medications, with a primary focus on studies involving children.",
author = "Turner, {Stephen W.}",
year = "2009",
month = "4",
doi = "10.2165/01250444-200913020-00006",
language = "English",
volume = "13",
pages = "127--135",
journal = "Molecular Diagnosis & Therapy",
issn = "1177-1062",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Genetic predictors of response to therapy in childhood asthma

AU - Turner, Stephen W.

PY - 2009/4

Y1 - 2009/4

N2 - Asthma is a common chronic condition in children, where the response to treatment can be heterogeneous within a population. Genetic variations may partly explain the inconsistent response to asthma treatment between individuals. There is a relatively small but consistent body of literature linking genetic variations to improved response to different classes of asthma treatment, including short- and long-acting ß-agonists, corticosteroids, and leukotriene modifiers. In most cases, the advantage conferred by a single genetic mutation for treatment response is relatively small; the Arg16Gly single nucleotide polymorphism of the ß2-adrenoceptor is the exception to this rule and is associated with a marked difference in response to short-acting ß-agonists. Pharmacogenetic studies have only recently been undertaken in asthmatic individuals, and much more work is required before clinical applications arise. Future genome-wide association (GWA) studies and randomized controlled trials in genetically susceptible populations will determine whether asthma treatment can be tailored to an individual based on their DNA. The aim of the present paper is to review pharmacogenetic studies concerning asthma medications, with a primary focus on studies involving children.

AB - Asthma is a common chronic condition in children, where the response to treatment can be heterogeneous within a population. Genetic variations may partly explain the inconsistent response to asthma treatment between individuals. There is a relatively small but consistent body of literature linking genetic variations to improved response to different classes of asthma treatment, including short- and long-acting ß-agonists, corticosteroids, and leukotriene modifiers. In most cases, the advantage conferred by a single genetic mutation for treatment response is relatively small; the Arg16Gly single nucleotide polymorphism of the ß2-adrenoceptor is the exception to this rule and is associated with a marked difference in response to short-acting ß-agonists. Pharmacogenetic studies have only recently been undertaken in asthmatic individuals, and much more work is required before clinical applications arise. Future genome-wide association (GWA) studies and randomized controlled trials in genetically susceptible populations will determine whether asthma treatment can be tailored to an individual based on their DNA. The aim of the present paper is to review pharmacogenetic studies concerning asthma medications, with a primary focus on studies involving children.

U2 - 10.2165/01250444-200913020-00006

DO - 10.2165/01250444-200913020-00006

M3 - Article

VL - 13

SP - 127

EP - 135

JO - Molecular Diagnosis & Therapy

JF - Molecular Diagnosis & Therapy

SN - 1177-1062

IS - 2

ER -